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The sequencing of the human genome, now well over adecade ago,1 provided important new insights into thevariation of sequence elements present in the genome.
An immediate question that surfaced was how one single
genome can give rise to all the different cell types of the human
body, and how all these different cell types know how and
when to interpret these genomic elements. Since then, it has
become widely appreciated that this regulation of DNA ele-
ments is closely connected to how the DNA is packaged with-
in the nucleus of each individual cell. This packaging is orches-
trated via chromatin, the complex of DNA, RNA and proteins
that provides functionality to the genome. Chromatin is, in
contrast to DNA, highly dynamic, and this plasticity is
achieved through placing chemical tags on cytosines at the
DNA level and on histones at the nucleosome level providing
an index or blueprint on top of the genomic information in dif-
ferent cellular environments (Figure 1).2,3 The field of epigenet-
ics aims to define the combination of chemical tags that index
the genome, how these marks are recognized and how this
translates into specific gene regulation and interpretation of the
functionality of DNA elements. Initially, epigenetic studies
focused on single loci or genomic regions of several kilobases,
but technological advances in recent years have for the first
time allowed the establishment of genome wide epigenomic
maps of individual cell types. To face the challenge of the plas-
ticity and the shear number and diversity of epigenetic marks,
worldwide consortia have been founded which aim to estab-
lish epigenomic maps of different kinds for a variety of species.
Specific for human, these efforts are coordinated by the
International Human Epigenome Consortium (IHEC;
http://www.ihec-epigenomes.org/) that aims to deliver 1,000 refer-
ence epigenomes for human cell types. Within IHEC, quality
standards are set for every aspect of epigenomic mapping, from
experimental setup and metadata collection to data storage and
primary analysis. Moreover, it provides communication plat-
forms that allow data sharing and minimizes redundancy
between different individual research projects. Currently, seven
epigenomic projects have been initiated and more are expected
to join IHEC in the coming years.
BLUEPRINT (www.blueprint-epigenome.eu) represents the
European initiative to establish epigenomic maps. BLUE-
PRINT4 has chosen to focus on generating epigenomic maps of
a wide variety of cell types from the blood, and to provide at
least 100 reference epigenomes as a resource to the scientific
community. These reference epigenomes will include primary
human cells from healthy individuals but also blood-based dis-
eases. The reference epigenomes from healthy individuals will
provide an important framework for understanding normal
hematopoiesis as well as providing a reference point for
epigenomes generated for hematologic malignancies such as
autoimmune diseases and common leukemias of myeloid and
lymphoid origin. Of the latter, BLUEPRINT will include several
of the most prevalent and clinical B-cell malignancies in adults
and children, i.e. chronic lymphocytic leukemia, follicular lym-
phoma, diffuse large B-cell lymphoma and Burkitt’s lymphoma
that are already subjected to complete genomic and RNA
sequencing in two European ICGC (http://icgc.org) projects,5
thereby further facilitating genome versus epigenome compar-
isons. 
The BLUEPRINT project, which was initiated in the fall of
2011, celebrated its first data release last April when 12 full
epigenomes of neutrophils and monocytes from both adult
blood and cord blood became available through different data
portals including the ENSEMBL6 and UCSC7 browsers, BIO-
MART8 and a visual interface developed by GENOMATIX.9
For each sample, the release included information on 6 IHEC
recommended informative histone modifications (H3K4me1,
H3K4me3, H3K27ac, H3K36me3, H3K9me3 and H3K27me3)
(Figure 2), on DNA methylation at base pair resolution, on
RNA expression, and on genome-wide accessibility through
DNAseI-seq analysis. Future releases will also include epige-
nomic data on differentiation pathways, such as monocyte to
macrophage and B-cell differentiation, and from more rare cell
types from healthy donors as well as on diseased cell types.
As an epigenomic project specifically focusing on
hematopoiesis, BLUEPRINT is expected to make a major con-
tribution to the field of blood epigenetics. The epigenomic
maps generated within BLUEPRINT will provide comprehen-
sive indexes of chromatin organization and associated func-
tionality that will serve as an entry point for further investiga-
tions into the key transcription factors and regulatory networks
that establish, regulate or maintain epigenomic features.10
Within one cell type, the epigenomic maps will allow the iden-
tification of gene classes with similar patterns of epigenetic fea-
Figure 1. Schematic overview of epigenetic modifications and effects on
chromatine structure and accessability of genes.
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tures that likely represent clusters with coordinated regula-
tion of gene expression. Upon systematic comparisons
between cell types, clusters of genes may prove to be coor-
dinately regulated by epigenetic mechanisms throughout
the hematopoietic differentiation program.11,12 In addition,
chromatin state maps identification will allow assignment
of the functional states (such as active, inactive or poised)
based on epigenetic profiles. The analysis will divide the
genome into epigenetic segments comprising combinations
of different epigenetic features such as DNA methylation,
histone modifications and accessibility13 and relate these to
function. The identification of such segments and compari-
son with perturbed epigenetic landscapes in disease will
trigger investigations into the restoration or repair of the
epigenetic code of these elements.  
Another goal of BLUEPRINT will be to investigate epige-
netic variation between individuals by studying two cell
types from at least 200 healthy donors, while a third cell
type from the same donors will be analyzed by a Canadian
IHEC project (http://ihec-epigenomes.org/research/projects/epige-
nomic-platform-program/). These donors will be subjected to
complete genome sequencing by the Wellcome Trust
Sanger Institute, as well as part of the UK10K project
(http://www.uk10k.org/) allowing epigenetic and genetic vari-
ation to be correlated. As the epigenome is expected to be
more plastic and influenced by many environmental fac-
tors, including diet, age and environmental exposure,14 a
likely finding will be that the epigenomes are more variable
between individuals then their genomes. Moreover, it will
reveal the natural epigenetic variation between cell types
from different individuals and to what extent this variation
is influenced by variations in the genome sequence. In addi-
tion, it will be extremely interesting to investigate the
extent to which epigenetic variation is translated into differ-
ential gene expression. 
BLUEPRINT will also set out to predict consequences of
sequence variants such as those linked to disease and there-
by create a better understanding of the relationship
between genetics and epigenetics. For example, since most
SNPs identified in genome-wide association studies are
located outside of protein coding genes,15 epigenomic map-
ping allows the functional characterization of a regulatory
region, for example by identifying new or alternative pro-
moters, poised or active enhancers. Moreover, the DNAseI-
seq experiment can be extended to footprint analysis16 that
will allow the putative identification of transcription factor
binding to a particular genomic location and can, in relation
with GWAS studies, also predict whether binding of tran-
scription factor(s) will be disturbed or gained. Apart from
the sequence variation in regulatory regions, BLUEPRINT
will also investigate the genome-wide effects of epigenetic
gene mutation. Many of the disease epigenomes will be
determined in leukemias that, as in many other cancers,
contain defects in main epigenetic regulators such as MLL
(H3K4me3), DNMT3A (DNAme) and TET2 (DNA
demethylation) in subtypes of acute myeloid leukemia.17
Comparisons between these and reference epigenomes
form healthy donors is expected to further unravel how dis-
turbance of epigenetic mechanisms facilitate the acquisition
of the hallmarks of cancer.18,19 As, in contrast to genetic
changes, these epigenetic modifications are reversible,
BLUEPRINT has also initiated studies that focus on epige-
netic drug treatment. These include efforts to identify com-
pounds that modulate epigenetic regulators as well as to
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Figure 2. (A) Schematic overview of histon modifications. (B)
Structure of a nucleosome: DNA wrapped around a cluster of 8 his-
tone proteins (H2A, H2B, H3, H4, each two times present). 
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identify novel epigenetic targets through RNA interference
approaches. 
As far as clinical impact is concerned, BLUEPRINT will
nurture the identification of biomarkers, specifically focus-
ing on the discovery of novel epigenetic biomarkers.
Epigenomes hold great promise as discovery engines for
identification of a disease state or environmental influence
(e.g. exposure to toxins, infections, drugs of abuse or psy-
chosocial stress) and thus will be useful for diagnosis, prog-
nosis or monitoring disease progression and remission.
Within BLUEPRINT, biomarker development will focus on
analyzing DNA methylation in childhood acute lym-
phoblastic leukemia both for prognosis and personalized
therapy, and on myeloid diseases, specifically acute
myeloid leukemia and myelodysplastic syndrome, for
determining the efficacy of epigenetic drug treatment.  
Finally, since BLUEPRINT represents one of the founding
human epigenomic projects within IHEC, it has developed
together with other IHEC consortia and ENCODE
(http://genome.ucsc.edu/ENCODE/) standards for other epige-
netic projects to produce, analyze, and integrate large
datasets and will maintain this function. A main challenge
within BLUEPRINT, as also in other epigenomic projects, is
that the full spectrum of hematopoietic cell types from the
stem cell to fully differentiated cells entails analysis of abun-
dant cell types such as monocytes and neutrophils, as well
as more rare or ultra rare cell types such as hematopoietic
stem cells. Primary hematopoietic stem cells and progeni-
tors cannot be obtained in sufficient quantities to perform
full epigenomic mapping using existing methods.
Therefore, BLUEPRINT is investing in developing new
miniaturization technologies to allow high throughput
mapping of the more rare blood cell types. As such, based
on ongoing efforts and future projects, BLUEPRINT will
continue to provide important guidance and guidelines for
further epigenomic mapping. These will not be restricted to
experimental issues, but will also be extended to data analy-
sis, especially focusing on large-scale epigenomic data inte-
gration that remains one of the major challenges within
these multidimensional projects. 
BLUEPRINT, as the first so-called high impact EU
research initiative project, can be expected to make signifi-
cant contributions to our understanding of the hematopoi-
etic epigenome, both in health and disease. We anticipate
that these will ultimately facilitate the development of new
predictors of disease, as well as providing new entry points
for diagnosis and drug therapies.
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